{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,2,21]],"date-time":"2025-02-21T12:24:17Z","timestamp":1740140657346,"version":"3.37.3"},"reference-count":25,"publisher":"Oxford University Press (OUP)","issue":"9","license":[{"start":{"date-parts":[[2024,8,19]],"date-time":"2024-08-19T00:00:00Z","timestamp":1724025600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2024,9,6]]},"abstract":"<jats:title>Abstract<\/jats:title>\n               <jats:p>The treatment landscape for acute myeloid leukemia (AML) is rapidly changing. Many new agents and lower-intensity regimens have been approved and can be safely used by hematologists and oncologists in both academic and community settings. The US Food and Drug Administration (FDA) held a virtual symposium on AML treatment in the community in November 2022. Several members of the FDA, along with practicing hematologists and oncologists in both academic and community settings, participated in the symposium. The goal of the symposium was to discuss challenges and opportunities in the treatment of patients with AML in community oncology settings. A summary of these discussions and key considerations are presented here.<\/jats:p>","DOI":"10.1093\/oncolo\/oyae051","type":"journal-article","created":{"date-parts":[[2024,8,19]],"date-time":"2024-08-19T16:53:20Z","timestamp":1724086400000},"page":"801-805","source":"Crossref","is-referenced-by-count":0,"title":["Treatment of Acute Myeloid Leukemia in the Community Setting"],"prefix":"10.1093","volume":"29","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-8359-0178","authenticated-orcid":false,"given":"Taha","family":"Al-Juhaishi","sequence":"first","affiliation":[{"name":"Oklahoma Health Sciences Center, University of Oklahoma , Oklahoma City, OK , USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Servillano","family":"Dela Cruz","sequence":"additional","affiliation":[{"name":"Florida Cancer Specialists & Research Institute , Inverness, FL , USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Rohan","family":"Gupta","sequence":"additional","affiliation":[{"name":"The Center for Cancer and Blood Disorders , Fort Worth, TX , USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Gina","family":"Keiffer","sequence":"additional","affiliation":[{"name":"Sidney Kimmel Cancer Center, Thomas Jefferson University , Philadelphia, PA , USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Vicki A","family":"Morrison","sequence":"additional","affiliation":[{"name":"Hennepin County Medical Center, University of Minnesota , Minneapolis, MN , USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Iuliana","family":"Shapira","sequence":"additional","affiliation":[{"name":"Regional Cancer Care Associates , Teaneck, NJ , USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ashley","family":"Woods","sequence":"additional","affiliation":[{"name":"Center for Drug Evaluation and Research, U.S. Food and Drug Administration , Silver Spring, MD , USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kelly","family":"Norsworthy","sequence":"additional","affiliation":[{"name":"Center for Drug Evaluation and Research, U.S. Food and Drug Administration , Silver Spring, MD , USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Romeo Angelo","family":"de Claro","sequence":"additional","affiliation":[{"name":"Center for Drug Evaluation and Research, U.S. Food and Drug Administration , Silver Spring, MD , USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Marc R","family":"Theoret","sequence":"additional","affiliation":[{"name":"Oncology Center of Excellence, U.S. Food and Drug Administration , Silver Spring, MD , USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ravin","family":"Garg","sequence":"additional","affiliation":[{"name":"Maryland Oncology and Hematology , Annapolis, MD , USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Elizabeth Dianne","family":"Pulte","sequence":"additional","affiliation":[{"name":"Center for Drug Evaluation and Research, U.S. Food and Drug Administration , Silver Spring, MD , USA"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"286","published-online":{"date-parts":[[2024,8,19]]},"reference":[{"volume-title":"SEER Cancer Stat Facts: Acute Myeloid Leukemia","key":"2024090704205328100_CIT0001"},{"key":"2024090704205328100_CIT0002","first-page":"823","article-title":"Does time from diagnosis to treatment affect the prognosis of patients with newly diagnosed acute myeloid leukemia","volume-title":"Blood","author":"R\u00f6llig","year":"2020"},{"key":"2024090704205328100_CIT0003","first-page":"1267","article-title":"Acute myeloid leukemia: 2019 update on risk-stratification and management","volume-title":"Am J Hematol","author":"Estey","year":"2018"},{"key":"2024090704205328100_CIT0004","first-page":"41","article-title":"Acute myeloid leukemia: current progress and future directions","volume-title":"Blood Cancer J","author":"Kantarjian","year":"2021"},{"key":"2024090704205328100_CIT0005","first-page":"659595","article-title":"Allogeneic stem cell transplantation for acute myeloid leukemia: who, when, and how","volume-title":"Front Immunol","author":"Loke","year":"2021"},{"key":"2024090704205328100_CIT0006","first-page":"635","article-title":"Eligibility criteria for patients undergoing allogeneic hematopoietic cell transplantation","volume-title":"J Natl Compr Canc Netw","author":"Kanate","year":"2020"},{"key":"2024090704205328100_CIT0007","first-page":"123","article-title":"Optimizing management of acute leukemia in community centers and when to refer","volume-title":"Hematology Am Soc Hematol Educ Program","author":"Jillella","year":"2020"},{"key":"2024090704205328100_CIT0008","first-page":"4163","article-title":"Accuracy of SIE\/SIES\/GITMO consensus criteria for unfitness to predict early mortality after intensive chemotherapy in adults with AML or other high-grade myeloid neoplasm","volume-title":"J Clin Oncol","author":"Palmieri","year":"2020"},{"key":"2024090704205328100_CIT0009","first-page":"181","article-title":"Assessing eligibility for treatment in acute myeloid leukemia in 2023","volume-title":"Expert Rev Hematol","author":"Venditti","year":"2023"},{"key":"2024090704205328100_CIT0010","first-page":"2386","article-title":"Durable remissions with ivosidenib in IDH1-mutated relapsed or refractory AML","volume-title":"N Engl J Med","author":"DiNardo","year":"2018"},{"key":"2024090704205328100_CIT0011","first-page":"463","article-title":"Ivosidenib induces deep durable remissions in patients with newly diagnosed IDH1-mutant acute myeloid leukemia","volume-title":"Blood","author":"Roboz","year":"2020"},{"key":"2024090704205328100_CIT0012","first-page":"e46","article-title":"Olutasidenib alone or with azacitidine in IDH1-mutated acute myeloid leukaemia and myelodysplastic syndrome: phase 1 results of a phase 1\/2 trial","volume-title":"Lancet Haematol","author":"Watts","year":"2023"},{"key":"2024090704205328100_CIT0013","first-page":"722","article-title":"Enasidenib in mutant IDH2 relapsed or refractory acute myeloid leukemia","volume-title":"Blood","author":"Stein","year":"2017"},{"key":"2024090704205328100_CIT0014","first-page":"454","article-title":"Midostaurin plus chemotherapy for acute myeloid leukemia with a FLT3 mutation","volume-title":"N Engl J Med","author":"Stone","year":"2017"},{"key":"2024090704205328100_CIT0015","first-page":"1728","article-title":"Gilteritinib or chemotherapy for relapsed or refractory FLT3-mutated AML","volume-title":"N Engl J Med","author":"Perl","year":"2019"},{"key":"2024090704205328100_CIT0016","first-page":"7","article-title":"Venetoclax combined with decitabine or azacitidine in treatment-naive, elderly patients with acute myeloid leukemia","volume-title":"Blood","author":"DiNardo","year":"2019"},{"key":"2024090704205328100_CIT0017","first-page":"113","article-title":"Gemtuzumab ozogamicin for de novo acute myeloid leukemia: final efficacy and safety updates from the open-label, phase III ALFA-0701 trial","volume-title":"Haematologica","author":"Lambert","year":"2019"},{"key":"2024090704205328100_CIT0018","first-page":"1181","article-title":"Clinical benefit of glasdegib plus low-dose cytarabine in patients with de novo and secondary acute myeloid leukemia: long-term analysis of a phase II randomized trial","volume-title":"Ann Hematol","author":"Heuser","year":"2021"},{"key":"2024090704205328100_CIT0019","first-page":"1571","article-title":"Quizartinib plus chemotherapy in newly diagnosed patients with FLT3-internal-tandem-duplication-positive acute myeloid leukaemia (QuANTUM-First): a randomised, double-blind, placebo-controlled, phase 3 trial","volume-title":"Lancet","author":"Erba","year":"2023"},{"issue":"4","key":"2024090704205328100_CIT0020","first-page":"485","article-title":"Cytosine arabinoside (NSC-63878) and daunorubicin (NSC-83142) therapy in acute nonlymphocytic leukemia","volume":"57","author":"Yates","year":"1973","journal-title":"Cancer Chemother Rep"},{"key":"2024090704205328100_CIT0021","first-page":"4280","article-title":"Differentiation syndrome with ivosidenib and enasidenib treatment in patients with relapsed or refractory IDH-Mutated AML: A U.S. Food and Drug Administration Systematic Analysis","volume-title":"Clin Cancer Res","author":"Norsworthy","year":"2020"},{"key":"2024090704205328100_CIT0022","first-page":"2249","article-title":"Immune checkpoint inhibition in acute myeloid leukemia and myelodysplastic syndromes","volume-title":"Cells","author":"Abaza","year":"2022"},{"key":"2024090704205328100_CIT0023","first-page":"e261","article-title":"CAR-T in B-cell lymphomas: the past, present, and future","volume-title":"Clin Lymphoma Myeloma Leuk","author":"Al-Juhaishi","year":"2022"},{"key":"2024090704205328100_CIT0024","first-page":"1843","article-title":"T-cell-based immunotherapy of acute myeloid leukemia: current concepts and future developments","volume-title":"Leukemia","author":"Daver","year":"2021"},{"year":"2023","author":"FDA","key":"2024090704205328100_CIT0025"}],"container-title":["The Oncologist"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/academic.oup.com\/oncolo\/article-pdf\/29\/9\/801\/59036699\/oyae051.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/oncolo\/article-pdf\/29\/9\/801\/59036699\/oyae051.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,9,7]],"date-time":"2024-09-07T05:03:17Z","timestamp":1725685397000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/oncolo\/article\/29\/9\/801\/7736053"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,8,19]]},"references-count":25,"journal-issue":{"issue":"9","published-online":{"date-parts":[[2024,8,19]]},"published-print":{"date-parts":[[2024,9,6]]}},"URL":"https:\/\/doi.org\/10.1093\/oncolo\/oyae051","relation":{},"ISSN":["1083-7159","1549-490X"],"issn-type":[{"type":"print","value":"1083-7159"},{"type":"electronic","value":"1549-490X"}],"subject":[],"published-other":{"date-parts":[[2024,9]]},"published":{"date-parts":[[2024,8,19]]}}}